Clinical Trials Logo

Clinical Trial Summary

Induction of labour (where labour is started artificially) is traditionally carried out with a range of different drugs or by surgery (rupturing the membranes or 'waters'). Dilapan-S is a mechanical device, known as an osmotic cervical dilator, which provides an alternative to drugs or surgery. Thin rods of an absorbent material (no active drug present) are inserted into the neck of the womb (cervix) and, as they absorb fluid, they swell and mimic the natural process of 'ripening' (or preparing) the cervix. This initial process is important before contractions begin. Unlike drugs, Dilapan-S does not cause premature contractions that, when too frequent, may cause the baby to become distressed. The project will compare cervical ripening using Dilapan-S with the standard use prostaglandin drug. Women with a single pregnancy, who require induction of labour, and who are not considered high risk, will be invited to participate. Investigators hope to recruit 860 women from UK maternity units over 2 years. Participants will have an equal chance of being randomised to the drug, which is standard practice, or the cervical dilator. The speed in which labour commences, the mode of delivery and any side effects will be compared. Importantly, investigators shall also assess patient satisfaction and anxiety during the induction process, by asking participants to complete a short questionnaire about their experience before they go home after having their baby. If osmotic dilators are effective investigators expect NICE to consider them an option alongside other cervical ripening methods.

Clinical Trial Description

Prospective, Phase III, UK, Open, Multicentre, Superiority, Randomised Controlled Trial of a CE marked medical device and an Investigational Medicinal Product (CTIMP). Potentially eligible patients will be identified by their obstetrician or midwife, based on the need for induction of labour. Once the decision to induce labour is made, women will be approached to participate in the trial and will be given a patient information leaflet (PIL) enclosed in the induction admission letter. Patients wishing to enter the trial will be confirmed for eligibility by an obstetrician. Prior to patients undertaking any trial-related procedures, informed consent will be obtained. Participants will then be randomised in a 1:1 ratio to either 1) synthetic osmotic cervical dilator or 2) a 10-mg controlled-release dinoprostone vaginal insert. Randomisation will be provided by a computer generated programme. A research assistant discloses the nature of the assignment only after enrolment. Investigators have calculated that 860 patients (430 in each arm) will need to be recruited over a 2 year period. Given the nature of the intervention, the SOLVE trial will not be a blinded trial. Full data collection will be conducted for those patients giving informed consent, from medical records. This will include baseline data, and details of mother and child at birth. Patients will also be asked to complete a maternal satisfaction questionnaire before they are discharged. There will be no further follow-up of patients post-discharge from care unless a Serious Adverse Event requires this. If the patient withdraws her consent during the study, data collection will be stopped. Only anonymised data will be entered into the Case Report Forms (CRFs) by the study team. Details of all patients approached about the trial will be recorded on the trial Screening Log, and fully anonymised copies returned to the trials office for review. ;

Study Design

Related Conditions & MeSH terms

  • Induction of Labor Affected Fetus / Newborn

NCT number NCT03001661
Study type Interventional
Source Birmingham Women's NHS Foundation Trust
Status Completed
Phase Phase 3
Start date December 19, 2017
Completion date February 6, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04492150 - Effect of Glucose 5% on Labor Length N/A
Not yet recruiting NCT03625518 - Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes Early Phase 1
Recruiting NCT04496908 - Early Versus Delayed Artificial Rupture of Membranes (AROM Trial) Early Phase 1
Recruiting NCT04478942 - PROMMO Trial: Oral Misoprostol vs IV Oxytocin Early Phase 1
Completed NCT03682718 - Vaginal Misoprostol With Intracervical Foley Catheter in Induction of Labor Phase 4
Recruiting NCT03533699 - A Comparison Between the Effect of Oxytocin Only and Oxytocin Plus Propranolol on Induction of Labor in Term Pregnancy N/A
Recruiting NCT02975167 - Patient Satisfaction During Outpatient Versus Inpatient Foley Catheter Induction of Labor N/A
Completed NCT03544606 - Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor Phase 3
Completed NCT03822052 - The Use of D5LR Versus LR for Induction of Labor and Time to Delivery in Multiparous and Primiparous Patient's With Favorable and Unfavorable Bishop's Scores N/A
Active, not recruiting NCT04220320 - The Success of Labor Induction Based on a Modified BISHOP Score.
Completed NCT04597333 - Labor Induction After Failed Induction With Dinoprostone. N/A
Completed NCT03086967 - Cervical Ripening With a Double-lumen Balloon Catheter for Six Versus Twelve Hours N/A
Completed NCT04299854 - Modality of Induction of Labor in Obese Women at Term (MODOBAT)
Recruiting NCT03944187 - Sonographic Assessment for Prediction of Labor Induction Success
Recruiting NCT03928899 - The Best Timing of Delivery in Women With GDM Study N/A
Not yet recruiting NCT04350437 - Induction Of Labor: Predictors of Outcomes N/A
Terminated NCT04011098 - Improving Labour Induction Analgesia: Epidural Fentanyl Bolus at Epidural Initiation for Induction of Labour Phase 1
Completed NCT02952807 - Vaginal Misoprostol and Foley Catheter for Induction of Labor Phase 2
Completed NCT03658590 - Dexamethasone and Induction of Delivery Phase 1
Completed NCT04536753 - The Utility of Customised Growth Charts for Identifying Macrosomia and the Effect of Intervention